# Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

> **NCT04954287** · PHASE1 · COMPLETED · sponsor: **CyanVac LLC** · enrollment: 72 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** CVXGA1 low dose
- **BIOLOGICAL:** CVXGA1 high dose

## Key facts

- **NCT ID:** NCT04954287
- **Lead sponsor:** CyanVac LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2023-06-10
- **Final completion:** 2023-06-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954287, "Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04954287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*